cystic fibrosis Flashcards

1
Q

exocrine pancreas - 2 stages in secretion

A

by 1994 it was decided by the field that cftr was a chloride Channel
the acinar cells
- which secrete the digestive enzymes
-but this is of no use if you’ve not got an efficient mechanism for transporting the enzymes and that requires the secretion of bicarbonate and water.
- So you have a bicarbonate Rich fluid and that’s what the ductile cells do
- and cftr is responsible in large part for that.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

CFTR and the pancreas

A

-CFTR expressed in pancreatic duct, so CF primarily affects ductal fluid secretion
- acinar secretion not directly affected but enzymes dont reach the intestine -> auto digestion (pancreatic insufficency
- with increased life expectancy -> autodigestion gradually destroys islet cells _> diabetes observed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

ductal cell - basolateral transporters

A

carbonic anhydrase activity was found to be insufficient to support the secretion

steward and Ishiguro demonstrated NBCe1 (function) is vital for secretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

studies in rat and mice suggesting CFTR might be responsible for chloride secretion

A

studies in rats and mouse suggested that cftr might be responsible for chloride secretion.
it was suggested that there might be a chloride bicarbonate exchanger coupled to cftr that was responsible for the bicarbonate secretion.
- However, the protein responsible for this is in Electro neutral chloride bicarbonate exchanger called ae2 anion exchanger 2
- but again, this model can’t explain the huge amounts of bicarbonate that’s secreted. It just isn’tefficient enough

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

korean studies on chloride and bicarbonate secretion

A

the idea is that cftr, despite being thought of as a chloride Channel and not the bicarbonate Channel, might be responsible for the actual chloride secretion.
- So there’s another Electrogenic chloride carbonate exchanger whose molecular identity is known as SLC 26A6
- This was discovered that might help to explain this because it provides the driving force for bicarbonate secretion. However, what is also required is a bicarbonate Channel
- and what they discovered is that cftr can switch from transporting chloride to transporting bicarbonate depending on the specific ion gradients and pH changes.

the evidence now suggests that the cftr is not just a chloride Channel, but it’s
also a bicarbonate permeable channel - transports bicarbonate under specific conditions to allow the bicarbonate to accumulate within the Lumen of the pancreatic duct.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

CFTR in the lungs

A

cystic fibrosis = decreased fluid at lung surface
-> thick viscous mucous
- impairs ‘much-cilliary escalator
- lungs become site of repeated infection
- chronic lung disease usual cause of death

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

lung - secretion and absorption

A

air surface liquid = balancing act between secretion and absorption

absorption depended on epithelial sodium channel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

surface of the epithelial lining of the lungs

A

-goblet cells that secrete mucus
- You’ve got the epithelial cells with a cilia attached that waft this mucus along the surface until it gets to the throat and this helps to remove the bacteria
- and you’ve got this air surface liquid layer and there’s in it’s a real Balancing Act in terms of both secretion and absorption.
○ So you’ve got chloride that’s being secreted. But you’ve also got sodium that’s been reabsorbed.
○ And this absorption of sodium is governed by an epithelial sodium Channel or ENaC
and the balance of these two ion fluxes is absolutely essential for this the movement of this mucus layer on the top.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what happens with secretion and absorption with the disease cysstic fibrosis

A
  • in the disease cystic fibrosis, there’s a lack of functional cftr which you would obviously deduce would prevent secretion of sodium chloride.
  • therefore there’s less fluid secreted producing this thick mucus layer
  • however, Cftr expression also inhibits ENaC activity. So if this is lost then there’s an increase in ENaC activity which makes the whole thing even worse.
    ○ So you end up having more sodium chloride being absorbed even though there’s less of it being secreted.
    ○ so you end up with this really thick mucus layer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

bicarbonate secretion

A

thick mucous in CF observed in epithelia which secrete bicarbonate e.g. pancreatic duct, intestine, uterus, etc.
- further hypothesised that they airways must secrete bicarbonate
- bicarbonate facilitates the unfolding of mucous glycoproteins as they are secreted - so that they have that lubricating sort of property to allow the
movement of that thick mucus layer to the surface

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

types of defects in CF

A

the types of defects that might occur in the disease based on the many different mutations.
- So you could have a defect in the synthesis of the protein, or the trafficking, or the folding and then trafficking of the protein to the apical surface of the cells
○ So that defect means that they’ll be less protein at the membrane to transport chloride or bicarbonate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

correctors and potentiators for treatment of CF

A
  • there are drugs that could act as correctors to help get the protein in the membrane
  • and then there are drugs that can be potentiators, So once they’re in the membrane that can actually increase the activity of the channel in the membrane,
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is CF caused by

A

cf is not caused by a single mutation. It’s caused by a single Gene,
- In fact, there’s around about 2,000 separate mutations that have been identified.
- That doesn’t mean that all of these are going to lead to a defect
there’s about 300 mutations that cause the disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

severe classes of mutations

A

class 1 - no protein sysnthesised
class 2 - defective maturation
class 3 - disordered regulation = decreased Po

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

potentiators - class 3

A

Target primarily the class three mutations where there’s a reduction in the open probability, but no changing current

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

how did they identify potentiators that could affect some of these mutant channels

A
  • You identify a functional screen and you can add every single compound that’s out of your library and test them against your functional screen and they identified VX 770
    ○ and what this shows using patch-clamp electrophysiology that there’s an increase in open probability of the cftr mutations such as this G55 1D
    ○ so you can see that there’s an increasing open probability - there open more often than not
    ○ and you still need PKA to be there as well, but you can see there’s just more openings.
16
Q

clinical improvements in patients after using VX-770

A

it causes quite a substantial clinical effect.
- quite a substantial change in body weight.
○ So it’s clearly affecting the gastrointestinal tract which means that your secreting more digestive enzymes.
○ It’s improving the breakdown of your food and absorption of nutrients.
- sweat chloride is another
○ There is a massive reduction in sweat chloride - 50% Improvement in sweat chloride.
○ it’s only in patients that have one copy of this this mutation.

  • The lungs - positive effect.
    ○ This is absolute change In percent of predicted forced expiratory volume in one second- And this is quite a significant increase in lung function.So this drug is effective however It’s only affecting a small number of patients
17
Q

correctors for class 2

A

these are drugs that actually improve the trafficking of the protein to the membrane
90% have 1 copy of F508del (55% have 2 copies)

1st generation corrector = VX-809 (lumacaftor)

18
Q

F508del mutation

A

means you’ve got a phenyl alanine at position 508 - this is deleted and it’s absolutely critical for the correct folding of the cftr
○ and that correct folding is required for glycosylation. So as it’s been trafficked and processed you get lots of glycosylation of the protein that helps it to be properly matured and trafficked to the plasma membrane
○ . If that’s defective then it doesn’t get to the plasma membrane.

19
Q

lumacaftor improvements

A
  • promotes glycosylation - increases trafficking to the mmebrane
  • increases short circuit current - functional measure of CFTR
  • but the drug was not good in phase 3 clinical trials
20
Q

combination of corrector and potentiator

A
  • VX-770 also increase Po of F508del
    -Combination improves the functional activty of the ion channel
  • Vast improvement of the corrector on its own
  • Orkambi licensed for treatments in 2015
21
Q

tezacaftor and ivacaftor - combination treatment

A

slightly better than orkambi
- fewer side effects

22
Q

triple therapy

A

tezacaftor + ivacaftor + VX-445
- VX-445 = next generation corrector

the three drugs working together is much more effective functionally
in getting more chloride transport.

using triple therapy that is likely to be effective in the vast majority of cystic fibrosis patients.